Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases

Ye, Xiaorong; Wang, Lifu; Xing, Yongjun; Song, Chengjun

doi:10.1186/s12876-020-01487-6

BMC Gastroenterology

Table 1 Clinical characteristics of small bowel cancer patients with liver metastases at diagnosis

From: Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases

Variable	Patients, no			Proportion of liver metastases, %		Survival among patients with liver metastases, median (IQR), mo
Variable	With small bowel cancer (n = 8831)	With metastatic disease (n = 2285)	With liver metastases (n = 1461)	Among entire cohort	Among subset with metastatic disease
Age
< 40	369	86	64	17.34	74.42	38.3 (18.0–59.0)
40–59	2998	782	509	16.98	65.09	38.7 (20.0–57.0)
60–79	4371	1136	727	16.63	64.00	33.5 (14.0–51.0)
≥ 80	1093	281	161	14.73	57.30	23.4 (2.0–40.0)
Race
Black	1485	365	241	16.23	66.03	32.8 (13.0–51.0)
White	6791	1806	1148	16.90	63.57	34.7 (15.0–54.0)
Others^a	465	110	69	14.84	62.73	31.7 (13.0–49.5)
Unknown	90	4	3	3.33	75.00	32.3 (16.0–50.3)
Gender
Male	4553	1179	765	16.80	64.89	34.0 (14.5–52.0)
Female	4278	1106	696	16.27	62.93	34.5 (14.0–53.0)
Insurance status
No	263	78	52	19.77	66.67	35.3 (12.0–59.0)
Yes	8373	2179	1390	16.60	63.79	34.2 (15.0–53.0)
Unknown	195	28	19	9.74	67.86	33.2 (14.0–51.0)
Marital status
Unmarried	3222	842	529	16.42	62.83	31.5 (12.0–50.0)
Married	5089	1339	859	16.88	64.15	36.0 (16.0–55.0)
Unknown	520	104	73	14.04	70.19	34.2 (16.0–53.8)
Primary site
Duodenum	3201	667	438	13.68	65.67	28.3 (8.0–46.0)
Jejunum	848	232	111	13.09	47.85	35.6 (17.0–54.0)
Ileum	2572	682	458	17.81	67.16	39.5 (21.0–57.0)
Other site^b	141	27	16	11.35	59.26	36.0 (16.0–56.5)
Unknown	2069	677	438	21.17	64.70	36.1 (17.0–55.0)
Grade
I	3704	691	464	12.53	67.15	37.9 (20.0–55.0)
II	1908	483	290	15.20	60.04	30.9 (13.0–48.0)
III	849	332	186	21.91	56.02	18.5 (3.0–27.0)
IV	125	77	27	21.60	35.06	29.9 (14.0–46.0)
Unknown	2245	1514	494	22.00	32.63	37.2 (14.0–60.5)
Histologic type
Adenocarcinoma	2457	886	506	20.59	57.11	20.0 (3.0–29.0)
NEC	5406	1205	863	15.96	71.62	39.5 (21.0–57.0)
GISS	968	194	92	9.50	47.42	41.1 (21.0–60.0)
T stage
T1	1382	157	98	7.09	62.42	33.2 (14.0–52.0)
T2	1306	157	114	8.73	72.61	40.8 (22.0–60.0)
T3	2767	627	418	15.11	66.67	38.4 (19.0–57.0)
T4	2128	803	427	20.07	53.18	29.7 (11.0–46.0)
Unknown	1248	541	404	32.37	74.68	27.1 (4.25–46.0)
Tumor size, cm
0–1	1518	86	52	3.43	60.47	38.3 (20.0–56.0)
1–2	1897	413	267	14.07	64.65	38.9 (20.0–57.0)
2–5	2523	751	488	19.34	64.98	34.7 (15.0–53.0)
> 5	1325	347	176	13.28	50.72	33.8 (14.0–52.0)
Unknown	1568	688	478	30.48	69.48	24.3 (16.0–42.0)
N stage
N0	4732	859	531	11.22	61.82	34.5 (14.0–54.0)
N1	3430	1096	728	21.22	66.42	36.7 (18.0–55.0)
N2	315	115	51	16.19	44.35	20.9 (7.0–29.0)
Unknown	354	215	151	42.66	70.23	18.9 (2.0–29.0)
M stage
M0	6546	6546	0	0.00	0.00	37.1 (18.0–56.0)
M1	2285	2285	1461	63.94	63.94	26.1 (6.0–42.0)
Extrahepatic metastatic sites to bone, lung, and brain, No
0	8488	1953	1255	14.79	64.26	35.0 (15.0–54.0)
1	243	243	142	58.44	58.44	14.1 (2.0–21.0)
2	16	16	9	56.30	56.30	9.5 (2.3–14.8)
Unknown	84	73	55	65.48	75.34	20.6 (1.3–36.8)
Surgery
No	1865	946	674	36.14	71.24	19.7 (3.0–30.0)
Yes	6935	1335	785	11.32	58.80	38.1 (19.0–56.0)
Unknown	31	4	2	6.45	50.00	36.7 (14.0–56.0)
Radiotherapy
No	8563	2177	1387	16.20	63.71	34.5 (15.0–53.0)
Yes	268	108	74	27.61	68.52	24.3 (9.0–37.8)
Chemotherapy
No	6820	1406	918	13.46	65.29	35.6 (16.0–55.0)
Yes	2011	879	543	27.00	61.77	29.7 (12.0–44.0)

IQR interquartile range, CI confidence interval, NEC neuroendocrine carcinoma, GISS gastrointestinal stromal sarcoma
^aAsian and American Indians
^bMeckels diverticulum, and overlapping lesion of small intestine

Back to article page

ISSN: 1471-230X

Contact us

General enquiries: journalsubmissions@springernature.com